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Abstract: Smoking is a major risk factor of morbidity and mortality. It is well established 
that  monoamine oxidase  (MAO)  activity is  decreased in  smokers.  Serotonin  (5-HT), a 
major substrate for MAO that circulates as a reserve pool stored in platelets, is a marker of 
platelet  activation.  We  recently  reported  that  smoking  durably  modifies  the  platelet  
5-HT/MAO system by inducing a demethylation of the MAO gene promoter resulting in 
high MAO protein concentration persisting more than ten years after quitting smoking. The 
present data enlarges the results to another MAO substrate, norepinephrine (NE), further 
confirming the central role of MAO in tobacco use-induced diseases. Thus, MAO could be 
a readily accessible and helpful marker in the risk evaluation of smoking-related diseases, 
from cardiovascular and pulmonary diseases to depression, anxiety and cancer. The present 
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review implements the new finding of epigenetic regulation of MAO and suggests that 
smoking-induced MAO demethylation can be considered as a hallmark of smoking-related 
cancers similarly to other aberrant DNA methylations. 
Keywords:  smoking;  serotonin;  norepinephrine;  monoamine  oxidase;  cardiovascular; 
platelets; epigenetic; cancer; depression 
 
1. Smoking Is a Prevalent Risk Factor of Morbidity and Mortality 
Tobacco use is the leading cause of preventable death and morbidity worldwide. Smoking is a 
modifiable risk factor for three major diseases, namely cardiovascular diseases, pulmonary diseases 
and cancer. This addictive disorder is responsible for one over five deaths and cardiovascular diseases 
is the leading cause of death from smoking. Among cardiovascular risks factors, smoking is second 
following  dyslipidemia,  with  no  threshold,  no  incidence  of  the  length  of  smoking  and  a  major 
prevalence among people less than 50 years for both sexes [1]. It is a major determinant of chronic 
obstructive pulmonary disease (COPD) and the most important risk factor of lung cancer.  
The molecular mechanisms underlying smoking-induced diseases are not fully understood, although 
all have in common systemic inflammation and oxidative stress. While nicotine is considered to be the 
major player underlying tobacco dependence [2], many other tobacco smoke  constituents are also 
involved  in  smoking-induced  dependence  and  diseases,  including  additives  to  enhance  the 
addictiveness [3-5]. Another target of smoking is obviously the mitochondria whose most fundamental 
function is the production of ATP in the cellular respiratory chain. Of the very few oxygen-dependent 
enzymes (aromatic amino acid hydroxylases and nitric oxide synthases for instance), the mitochondrial 
MAO have been shown to be impacted by smoking [6-8]. 
2. MAO and Smoking  
MAO (EC 1.4.3.4) are integral proteins of outer mitochondrial membranes devoted to the organism 
homeostasis protection.  They are major  enzymes  which  occur in  various  cells, both  neuronal and  
non-neuronal in the central nervous system (CNS) and peripheral organs. In the CNS, MAO not only 
plays  a  physiological  role  in  the  metabolic  inactivation  of  released  monoamine  transmitters 
(catecholamines, 5-HT) and in the detoxification of xenobiotic amines but also a pathophysiological 
role by generating cytotoxic free radicals during aging and neurodegenerative diseases. These enzymes 
are abundant in organs in direct relation with the environment: lungs, gastrointestinal tractus and liver. 
Their  main  function  is  to  proceed  an  oxidative  deamination  of  biogenic  amines,  both  exogenous 
(tyramine) and endogenous (NE, dopamine and 5-HT) in peripheral tissues and brain. Thus, MAO 
enzymes  are  involved  in  the  regulation  of  neurotransmitters  which  control  mood,  behaviour, 
movement,  memory,  appetite,  sleep  and  personality.  Their  inhibition,  by  either  exogenous  or 
pharmaceutical  substances,  leads  to  the  increase  of  the  above  monoamines  and  has  major 
consequences in the central nervous system.  
The first report that MAO activity is modified by smoking appeared in the early eighties in a mouse 
model [6] and in human cigarettes smokers [7]. It is only fifteen years later that Berlin et al. [8] Int. J. Environ. Res. Public Health 2011, 8                 
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measured  lower  activities  of  MAO  in  heavy  smokers.  Studies  using  PET-scan  showed  that  this 
inhibition occurs both in smokers’ peripheral tissues and different organs, lungs, kidneys, brain and 
spleen [9,10]. The reduction in brain MAO-B is widespread and the degree of inhibition is of the same 
order of magnitude than that found in platelets of current smokers. Such a large distribution of MAO 
accounts for the implication of these enzymes in cardiovascular diseases, pulmonary diseases, cancer 
and affective spectrum disorders.  
There are two MAO isoenzymes, MAO-A and MAO-B, which differ by their substrate specificity 
and  even  more  by  inhibitor  selectivity.  MAO-A  is  inhibited  by  low  concentrations  of  clorgyline 
whereas MAO-B is irreversibly inhibited by low concentrations of deprenyl. In humans, the highest 
concentrations  of  MAO-A  are  found  at  the  organism’s  barrier:  gut,  placenta,  lungs  and  liver, 
corresponding to the enzyme’s ontogenetic detoxifying function. High concentrations of MAO-B are 
found in glial cells and blood platelets. MAO-A preferentially deaminates bioamines of endogenous 
source such as 5-HT, epinephrine and NE, while MAO-B preferentially degrades exogenous bioamines 
ingested in the diet such as phenylethylamine and benzylamine [5,11]. Dopamine and tyramine are 
equally catabolized by both forms of MAO. These substrate specificities are relative, however, since, 
depending on conditions, all the above bioamines are substrates for both isoenzymes. End products of 
the MAO action on bioamines are aldehydes and H2O2 involved in oxidative processes. Aldehydes are 
either  oxidized  in  5-hydroxy  indol  acetic  acid  (5-HIAA)  for  5-HT  catabolism  or  reduced  in  
3,4-dihydroxyphenylglycol  (DHPG)  for NE catabolism. The  formation  of 5-HIAA  from 5-HT  via 
MAO is accompanied by the generation of ROS (see [5] for a review) which participate in smooth 
muscle cell proliferation, hypoxia and respiratory distress [12-14] and cancer growth [15]. 
The genes coding for MAO-A and MAO-B are both located on the short arm of the X chromosome 
[16].  Comparison  of  the  deduced  amino-acid  sequences  showed  that  MAO-A  and  MAO-B  have 
around  70%  amino-acid  sequence  identity.  The  two  genes  MAOA  and  MAOB  are  arranged  in  a  
tail-to-tail orientation, and both span at least 60 kb, consist of 15 exons, and exhibit an identical  
exon-intron  organization  [17].  The  promoter  regions  share  60%  sequence  homology  and  both 
promoters consist of GC-rich regions. Within the MAOA promoter region, a polymorphism has been 
shown to affect expression [18] and, using bioinformatics approaches, putative methylation targets 
have been identified [19]. The repeat 3 of VNTR polymorphism of MAOB intron 13 has also been 
implied into the men smoking predisposition when associated with the dopamine D2 receptor gene 
(DRD2) polymorphism [20]. An association between the 4-repeat allele of MAO-A functional VNTR 
promoter  polymorphism  and  the  tobacco  consumption  was  also  evidenced  in  caucasian  male  
patients [21]. Altogether, although still unclear, there is some evidence that MAO genetic factors could 
favour tobacco addiction and the resulting biogenic amine modulation. 
3. Bioamines Catabolism in Smokers  
It is well established that smoking modifies MAO,  but until recently, it was not clearly stated 
whether it is the enzyme amount or its activity which is smoking sensitive. In most of reports, it has 
been evaluated by PET [9,10,22]. The PET scan analysis of MAO allows to (i) mainly visualize the 
enzyme location and (ii) appreciate its concentration by a measure of the color deduced from the 
autoradiographic density. It does not allow, however, an accurate measure of the enzyme amount. The Int. J. Environ. Res. Public Health 2011, 8                 
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latter  also  applies  to  the  Western blot  technique,  which  allows  an  estimation  of MAO,  but  again 
quantitation of the band intensity  is only  approximate.  The only  real  quantitative  assessment is a 
radiochemical  assay  based  upon  the  binding  of  a  MAO  reversible  inhibitor,  as  developed  by  
Cesura et al. [23]. Such a technical point is of peculiar importance when accurate comparisons of 
MAO protein levels have to be performed, i.e., for instance between smokers and former smokers. 
With the aim to clarify whether tobacco use affects MAO activity and/or MAO amount, we used the 
biochemical assay described by Cesura et al. [23] and took advantage of the easy access to the MAO-B 
isoform contained in blood platelets to measure both its amount and its activity [24]. Following careful 
pre-analytical  conditions  for  blood  sampling,  two  major  MAO  substrates,  5-HT  and  NE,  were 
measured in blood platelets and in plasma of 115 men, respectively. Technical details can be found in 
references [8] and [24]. 
3.1. 5-HT and 5-HIAA 
It has been proposed that 5-HT could be predictive of coronary artery diseases, especially in young 
people [25]. In the latter report, it was not clear, however, which 5-HT pool was quantified, i.e., the 
platelet stored content or the plasma pool. This is of importance, since platelet 5-HT storage prevents 
5-HT-induced  vascular  effects.  Platelet  activation  is  associated  with  both  progression  of 
atherosclerosis and precipitating events leading to stenosed arteries [26,27]. Activated platelets release 
their  granule  content  which  leads  to  the  exposition  of  new  adhesive  receptors  and  secretion  of 
cytokines, RANTES and growth factors [28-30]. Among these released growth factors, serotonin is 
quantitatively the major one considering its millimolar concentration within platelet dense granules. 
High  plasma  serotonin  contributes  to  activate  lung  vascular  receptors  [31,32]  and  pulmonary 
hypertensive  complications  are  observed  [33].  In  in  vitro  experiments,  serotonin  induces  smooth 
muscle cell proliferation [34,35] and contributes to inflammatory and thrombotic activation of the 
vessels  [36].  In  atherosclerotic  mice,  platelet  serotonin  granule  secretion  plays  a  critical  role  in 
vascular  remodelling  [37].  And  so,  serotonin  receptor  blockers  are  potent  vasodilators  in  various 
cardiovascular diseases [38] and the serotonin receptor 5-HT2A antagonist ketanserin contributes to 
reduce neointimal proliferation [39]. 
In this context and considering that: (i) smoker’s platelets are activated [30,40] and (ii) cigarette 
smoke  directly  causes  platelet  activation  [41],  we  postulated  that  in  smokers’  platelets  the  
granule-stored 5-HT would be released and degraded by MAO. We thus performed a comparison 
between non smokers, smokers and former smokers of 5-HT and its catabolite 5-HIAA measured in 
isolated blood platelets and in plasma, respectively. Contrary to all expectations, platelet 5-HT was not 
found different in smokers and non-smokers but was lower in former smokers with a parallel higher 
plasma level of 5-HIAA [24]. Thus, our precise determination of platelet 5-HT content and plasma  
5-HIAA did not confirm that 5-HT could be a cardiovascular risk marker [25]: if platelet 5-HT and 
plasma 5-HIAA levels were both correlated with the cardiovascular risk reference—the Framingham 
risk score [24], after adjusting these correlations to the smoking status, it appeared that the determining 
risk factor among those taken into account in the Framingham risk calculation was smoking.  
The ―apparently normal‖ level of 5-HT in smokers’ platelets was unforeseen since MAO-B activity 
is inhibited in smokers [8-10,22,24]. The quantitative measure of MAO amount rendered our results Int. J. Environ. Res. Public Health 2011, 8                 
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coherent (Figure 1): in smokers and former smokers the smoking-induced inhibition of MAO activity 
is counter-balanced by higher enzyme amounts. After quitting smoking, MAO activity is no longer 
inhibited but the high amount of protein results in a higher 5-HT degradation into 5-HIAA. The MAO 
activity  did  not  correlate  with  any  studied  marker  other  than  platelet  5-HT  and  plasma  5-HIAA  
(P < 0.0001). The most striking results is that the high smoking-induced platelet MAO-B amount 
remains elevated several years after quitting smoking (mean 13 years). Further studies are needed, 
however, to: (i) determine the delay between the smoking start and the elevation of MAO-B protein 
concentration  and  (ii)  to  precisely  establish  how  long  after  quitting  smoking  this  effect  lasts. 
Preliminary unpublished data suggest a reversion of this increase of protein synthesis around 20 years 
after quitting smoking. 
Figure  1.  Platelet  MAO  in  smokers  (44  S),  non  smokers  (34  NS)  and  former  
smokers  (37  FS).  Left:  MAO  activity  (nmoles.mg  protein
–1h
–1)  Right:  MAO  amount  
(pmoles.mg protein
–1). **P < 0.001, ***P < 0.00001. 
 
3.2. NE and DHPG  
Because platelet NE amount is high, we also measured NE and DHPG in carefully drawn and 
processed plasma samples. Deamination of NE by MAO produces a reactive aldehyde that is reduced 
to form DHPG, a minor but MAO-specific NE catabolite. The highest NE plasma level was found in 
former smokers especially compared to never smokers (Figure 2 left). Fitting with the high level of 
plasma NE, its catabolite, DHPG, was higher in former smokers’ plasma as well (Figure 2 right). 
However, the DHPG/NE ratio was significantly (P < 0.01) lower for smokers (1.40 vs. 1.72 and 1.79 
for never smokers and former smokers, respectively) indicating a reduced MAO-A activity in smokers 
without  persistence  in  former  smokers.  Like  platelet  5-HT,  the  plasma  level  of  NE  significantly Int. J. Environ. Res. Public Health 2011, 8                 
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correlated with the MAO protein amount (P < 0.0001). Low platelet contents of 5-HT and high plasma 
levels  of  NE  in  former  smokers  are  consistent  with  a  high  MAO  amount  of  enzyme  active after 
quitting  smoking  [24].  Moreover,  as  for  platelet  5-HT,  plasma  NE  correlated  with  the  length  of 
smoking (p < 0.0009). 
Figure 2. Norepinephrine (NE, left) and its metabolite DHPG (right) in the plasma from 
non smokers (white bars), former smokers (FS dotted bars), and smokers (S hatched bars) 
**P < 0.001; Differences between FS and S were not significant (P > 0.05) for NE and the 
same applies between NS and S for DHPG. NE and DHPG were determined by HPLC 
with electrochemical detection as previously described [8]. 
 
4. Is MAO a Risk Marker? 
Among the population studied, the MAO-B amount correlates significantly with the number of 
atherosclerotic plaques, the number of atherosclerotic sites, especially the femoral sites [24]. It also 
correlated  with  the  duration  of  smoking  (Figure  3  left),  indicating  that  the  MAO-B  protein 
concentration is linked to the duration of smoking. At this point, an interesting observation comes to 
light. The median value of the MAO amount in our whole population was of 2.5 pmoles/mg platelet 
protein. For those for which MAO amount was over the median value, considered as a cut off value, it 
significantly correlated with the length of smoking (not shown): the longest time they smoked, the 
higher amount of MAO they had. By contrast, for those with less MAO than the cut off median value, 
there was no correlation with the duration of smoking. This holds also true for smokers. As illustrated 
on (Figure 3 right), only a MAO amount higher than 2.5 pmoles/mg platelet protein was correlated  
(P < 0.01) to the duration of smoking. This observation suggests that the duration of smoking has no 
incidence provided the MAO amount  before smoking is less than 2.5 pmoles/mg platelet protein. 
Furthermore,  whereas  only  27%  of  non  smokers  have  a  MAO  concentration  over  2.5  pmoles/mg 
platelet protein, it comes to 45% of smokers and 77% of former smokers. Altogether, this observation Int. J. Environ. Res. Public Health 2011, 8                 
 
142 
suggests that MAO-B amount could well be a morbidity determinant. Obviously this point should be 
studied in a larger population in order to really establish whether there may be a critical level of MAO 
concentration around 2.5 pmoles/mg platelet protein above which morbidity risk would be higher.  
Figure 3. Correlation between platelet MAO amount and duration of smoking. A: in the 
whole population (smokers S + former smokers FS + non smokers NS: n = 108, r = 0.25,  
P < 0.01) and B: in smokers (S) above the cut-off value (n = 18, r = 0.77, P < 0.01). 
 
5. Smoking-induced Epigenetic Modification of MAO  
A  persistent  increase  in  the  amount  of  MAO-B  lasting  over  10  years  after  quitting  smoking 
suggested a modification at the gene level. Indeed the smoking-induced variations of MAO expression 
are explained by a reduced methylation level of the MAOB promoter [24] (Figure 4), resulting in a 
more  active  transcription  of  the  MAO  and  hence  a  higher  MAO  amount.  The  higher  the  MAOB 
promoter is methylated, the lower MAO amount is found. Human MAOB core promoter comprises 22 
CpG sites that can be methylated, with methylation reducing the transcription  [42]. The extent of 
methylation of the MAOB promoter is markedly lower at almost all CpG methylation sites for smokers 
and former smokers compared to non smokers (from 59% to 25 and 27%, respectively), except sites 
n° 19 and 20. Moreover, the MAO level was positively correlated to the methylation extent of all sites  
(0.0002 < P < 0.003) except that of site n° 19. The study of a much larger series, using high-throughput 
technologies allowing more rapid direct measures of DNA methylation, would enable a more precise 
and detailed analysis. Such a study would allow defining if there are specific sites which are more 
determinant for smoking-induced risks through impact on MAO amount.  
How does such a DNA methylation occur? Based on experiments performed on an ex vivo animal 
model we proposed that tobacco smoke induces an increase of nucleic acid demethylase activity [24], 
possibly due to hyperactive poly (ADP-ribose) polymerases [43,44]. This may not apply to humans, 
however, because species differences in the enzymatic process cannot be excluded. Besides, since no 
DNA  demethylase  enzyme  has  yet  been  identified,  it  could  also  result  from  a  reversion  of  the 
transmethylase(s). Int. J. Environ. Res. Public Health 2011, 8                 
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Figure  4.  Methylation  of  the  22  CpG  sites  of  the  MAOB  promoter  in  PBMC  from  
non  smokers  (4  NS,  white  bars),  former  smokers  (4  FS,  dotted  bars)  and  smokers  
(5 S, hatched bars). The differences between NS and FS or S are significant at all sites  
(0.0001 < P < 0.02) except at sites 19–20. 
 
6. MAO in Smokers: From Cardiovascular Diseases to Mood Disorders 
Several data indicate that smoking is an anti-depressive addict (see [5] for a review]. Moreover, 
keeping in mind that for many years the prevailing hypothesis on depression is an absolute or relative 
deficiency of monoamines [45], the differences measured between smokers and non smokers could 
have implication in their respective behaviours. Despite the participants to our study were clearly not 
addicts since they came for an evaluation of their cardiovascular risk, about half of the participants 
were submitted to an anxiety-depression questionnaire (HAD test). Among the 68 participants, only 
5% had scores above the characteristic threshold for depression and anxiety, all of which were smokers. 
An obvious gradient from smokers (mean values of 4.5 and 7.6), to never smokers (3.2 and 6) and 
former smokers (2.3 and 6) appeared for the tendency to depression and anxiety, respectively.  In 
agreement  with  previous  reports,  the  smoker  group  was  the  most  proned  to  depression.  One  can 
therefore speculate that smokers need to inhibit their MAO by smoking instead of using a MAO 
inhibitor, the first class of antidepressants. As for the group of former smokers, not only they were the 
less depressed, but they were in a more euphoric mood than non smokers. This is to put together  
with  the  higher  plasma  levels  of  NE  of  former  smokers,  since  catecholamines  are  crucial  for  
affective disorders.  
7. Conclusions 
This review summarizes our recent finding that smoking durably reduces the methylation of the 
MAOB  promoter,  leading  to  an  increase  in  MAO-B  protein  synthesis.  In  other  words,  smoking 
provokes a higher MAO-B synthesis to compensate the  decreased enzyme activity due to oxygen Int. J. Environ. Res. Public Health 2011, 8                 
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deprivation. Despite the fact that both MAO-B and MAO-A activities are affected by smoking, it is 
important to underscore that the two MAO isoforms and the two unique genes encoding these enzymes, 
share  some  common  characteristics  but  also  have  unique  features.  In  smoking  women  a  similar 
approach  would  be  of  interest  to  explore  a  possible  gender  specificity  [46].  If  similar  epigenetic 
modification(s) upon one or both MAO isoform(s) are found in women, they may account—at least 
partially—for transgenerational consequences following in utero exposure to maternal smoking [47]. 
We also extended our results to point out that MAO-B could be a risk biomarker of smoking-induced 
morbidity, due to the role of the bioamines/MAO system in all smoking related diseases. This risk 
factor can easily be measured from a blood platelet sample. Its cut-off can be estimated at around  
2.5 pmoles/mg platelet protein, but has now to be precisely refined in larger series.  
A  holistic  approach  to  the  smoking  related  diseases,  i.e.,  cardiovascular  diseases,  pulmonary 
diseases, lung cancer, and mood disorders may be to further study the role of MAOs in these diseases. 
Smoking is the best example of lifestyle influence which considerably modifies the epigenetic patterns 
in various tissues (see [48] for a review] and MAOs might be a determinant component to explore the 
exposome [49]. Hopefully, epigenetic modifications are reversible and our preliminary results indicate 
that  the  decrease  in  DNA  methylation  is  back  to  normal  around  twenty  years  after  quitting.  The 
potential value of MAO-B as a smoking biomarker might therefore be of public health relevance to 
help in individual susceptibility evaluation and disease diagnosis and prognosis. 
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